DE602004020917D1 - Verfahren zur identifizierung von an der phosphoinositid-vermittelten signalgebung beteiligten verbindungen sowie verwendung davon bei der herstellung von arzneimitteln - Google Patents
Verfahren zur identifizierung von an der phosphoinositid-vermittelten signalgebung beteiligten verbindungen sowie verwendung davon bei der herstellung von arzneimittelnInfo
- Publication number
- DE602004020917D1 DE602004020917D1 DE602004020917T DE602004020917T DE602004020917D1 DE 602004020917 D1 DE602004020917 D1 DE 602004020917D1 DE 602004020917 T DE602004020917 T DE 602004020917T DE 602004020917 T DE602004020917 T DE 602004020917T DE 602004020917 D1 DE602004020917 D1 DE 602004020917D1
- Authority
- DE
- Germany
- Prior art keywords
- tapp
- sub
- interaction
- ptpl1
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 230000003993 interaction Effects 0.000 abstract 6
- 101001087422 Homo sapiens Tyrosine-protein phosphatase non-receptor type 13 Proteins 0.000 abstract 4
- 102100033014 Tyrosine-protein phosphatase non-receptor type 13 Human genes 0.000 abstract 4
- 150000003905 phosphatidylinositols Chemical class 0.000 abstract 3
- 230000001413 cellular effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0322689.1A GB0322689D0 (en) | 2003-09-27 | 2003-09-27 | Methods |
| PCT/GB2004/004060 WO2005031347A1 (en) | 2003-09-27 | 2004-09-27 | Methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004020917D1 true DE602004020917D1 (de) | 2009-06-10 |
Family
ID=29286978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004020917T Expired - Lifetime DE602004020917D1 (de) | 2003-09-27 | 2004-09-27 | Verfahren zur identifizierung von an der phosphoinositid-vermittelten signalgebung beteiligten verbindungen sowie verwendung davon bei der herstellung von arzneimitteln |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070054328A1 (de) |
| EP (1) | EP1687631B1 (de) |
| AT (1) | ATE430315T1 (de) |
| DE (1) | DE602004020917D1 (de) |
| DK (1) | DK1687631T3 (de) |
| GB (1) | GB0322689D0 (de) |
| WO (1) | WO2005031347A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111610247B (zh) * | 2020-05-27 | 2021-03-16 | 中国科学院地质与地球物理研究所 | 一种从地质样品中快速分离出高纯度w的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) * | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US5149796A (en) * | 1989-08-31 | 1992-09-22 | City Of Hope | Chimeric DNA-RNA catalytic sequences |
| US5180818A (en) * | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| US5114019A (en) * | 1991-08-20 | 1992-05-19 | Sandbank Mary E | Net for dishwasher rack |
| EP0789771A2 (de) * | 1993-09-01 | 1997-08-20 | Ludwig Institute For Cancer Research | Nukleotidsequenzen für neue proteintyrosinphosphatasen |
| US6521414B2 (en) * | 2000-02-01 | 2003-02-18 | Agy Therapeutics, Inc. | Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1 |
| ATE483728T1 (de) * | 2000-08-03 | 2010-10-15 | Medical Res Council | Tapp2 polypeptide |
| GB0118611D0 (en) * | 2001-07-31 | 2001-09-19 | Univ Dundee | Methods |
-
2003
- 2003-09-27 GB GBGB0322689.1A patent/GB0322689D0/en not_active Ceased
-
2004
- 2004-09-27 EP EP04768604A patent/EP1687631B1/de not_active Expired - Lifetime
- 2004-09-27 AT AT04768604T patent/ATE430315T1/de not_active IP Right Cessation
- 2004-09-27 WO PCT/GB2004/004060 patent/WO2005031347A1/en active Application Filing
- 2004-09-27 US US10/573,508 patent/US20070054328A1/en not_active Abandoned
- 2004-09-27 DE DE602004020917T patent/DE602004020917D1/de not_active Expired - Lifetime
- 2004-09-27 DK DK04768604T patent/DK1687631T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1687631A1 (de) | 2006-08-09 |
| US20070054328A1 (en) | 2007-03-08 |
| EP1687631B1 (de) | 2009-04-29 |
| GB0322689D0 (en) | 2003-10-29 |
| ATE430315T1 (de) | 2009-05-15 |
| WO2005031347A1 (en) | 2005-04-07 |
| DK1687631T3 (da) | 2009-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60324427D1 (de) | Verfahren zur modulation der tubulindeacetylase-aktivität | |
| DE60204966D1 (de) | Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis | |
| CY1107484T1 (el) | Παραγωγα γκελνταναμυκινης χρησιμοποιουμενα για τη θεραπεια καρκινου | |
| DE69524679D1 (de) | Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure | |
| DE60326273D1 (de) | Verfahren und verbindungen zur verstärkung der fybrozyten-bildung | |
| DE50002293D1 (de) | Verwendung von csf-1-inhibitoren | |
| ATE548354T1 (de) | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen | |
| DE60035575D1 (de) | Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie | |
| DE60027732D1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
| DE69727695D1 (de) | Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung | |
| ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
| DE69635213D1 (de) | Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen | |
| DE602004031631D1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
| DE602004020917D1 (de) | Verfahren zur identifizierung von an der phosphoinositid-vermittelten signalgebung beteiligten verbindungen sowie verwendung davon bei der herstellung von arzneimitteln | |
| DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| ATE542542T1 (de) | Verwendung von gp130 aktivatoren zur behandlung von diabetischer neuropathie | |
| ATE402694T1 (de) | Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz | |
| DE69301750D1 (de) | Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose | |
| DE60229240D1 (de) | Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes | |
| ATE252383T1 (de) | Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| ATE294582T1 (de) | Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs | |
| DE60224429D1 (de) | Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol | |
| ATE374025T1 (de) | Verbindungen zur beseitigung und/oder linderung der anhedonie | |
| ATE314066T1 (de) | Verwendung von buprenorphin zur therapie der harninkontinenz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |